Through our committed advocacy network, AIM has helped secure a seven-fold increase in Alzheimer’s and dementia research funding since the passage of the National Alzheimer’s Project Act (NAPA). Following a $226 million increase signed into law in December 2022, and added to current NIH spending, annual federal funding for Alzheimer’s research will be more than $3.7 billion.

Alzheimer's and Dementia Research Funding at the NIH

As a result of this unprecedented funding, scientists are able to work at a more rapid pace to advance basic disease knowledge, explore ways to reduce risk, uncover new biomarkers for early diagnosis and drug targeting, and develop potential treatments.

For decades, millions of Americans and their families have waited for improved, effective therapies for Alzheimer’s and other dementia. Around the globe, researchers are working to find solutions for those facing the crushing realities of this relentless disease.

Thanks to our tireless advocates, AIM helped achieve today’s unprecedented levels of Alzheimer’s research funding. This funding is directly empowering scientists to explore a wide variety of pathways that could yield promising new therapies for people living with Alzheimer’s in the future.

It’s an exciting time for Alzheimer’s and dementia research. At any given moment, discovery is happening. Learn more about these exciting developments in Realizing the National Plan to Address Alzheimer’s Disease: Leadership Toward Treatment and Prevention.


Two Advocates Outside

Be a Champion in the Fight to End Alzheimer’s

Our voices are stronger together. Help AIM advance legislation to improve the lives of people impacted by Alzheimer’s and all other dementia.

  • Share your story with elected officials
  • Engage on social media
  • Write a letter to the editor

Federal Priorities

Access to Treatment

A restrictive Centers for Medicare & Medicaid Services (CMS) policy that only applies to those living with Alzheimer’s disease is blocking access to FDA-approved treatments. CMS must reverse its unprecedented decision that denies Medicare coverage of current and future treatments for Alzheimer’s.

A National Response to Alzheimer’s and Other Dementia

The bipartisan NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act would build on the progress made over the last decade by continuing to promote rapid research and improve the delivery of clinical care and services for people living with Alzheimer’s.